Hologic (HOLX) Q4 2025 10-Q Quarterly Report
Filed: Jan 29, 2026Period ending Dec 27, 2025
Health Care
X-Ray Apparatus & Tubes & Related Irradiation ApparatusSEC EDGAR Hologic (HOLX) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Jan 29, 2026 for the fiscal period ending Dec 27, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Hologic Q4 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1.05B total ($831.4M product + $216.4M service), product revenues up 1.7% YoY from $817.9M, driven by GYN Surgical (+8.0%) and Skeletal Health (+124.3%), partially offset by declines in Diagnostics (-0.8%) and Breast Health (-2.2%)
- • Operating margin by segment: Diagnostics 33.9% vs 33.0% YoY (+0.9pp); Breast Health 27.3% vs 24.3% YoY (+3.0pp); GYN Surgical 22.4% vs 35.2% YoY (-12.8pp); Skeletal Health 10.5% vs -19.6% YoY (+30.1pp)
- • Best performing segment: Skeletal Health revenue +69.0% to $26.7M with improved operating income $2.8M vs loss $3.1M prior year; Worst performing: GYN Surgical lowest margin and operating income fell 30.9% despite 8.7% revenue increase
- • Cash and equivalents increased $208.5M to $2.17B; Operating cash flow $229.9M driven by net income $179.1M; Investing cash use $12.1M primarily capital expenditures and investments; Financing cash use $10.7M due to employee tax payments and equity plan proceeds
- • Management highlights ongoing Brevera 9 Gauge Needle stop-ship and recall weighing on Breast Health product revenues; merger agreement with Blackstone and TPG expected closing H1 2026; expects sufficient liquidity over next 12 months; cautious on COVID testing volume decline and macroeconomic risks
Risk Factors
- • Ongoing COVID-19 pandemic impact on supply chain and demand remains a key carried-forward risk
- • Dependency on third-party suppliers could disrupt manufacturing and affect revenue continuity
- • Regulatory scrutiny on diagnostic products could delay approvals or increase compliance costs
- • Competition from new entrants and technologies threatens market share and pricing power
- • Debt maturity schedule requires $600 million repayment by 2026, posing liquidity pressure
Hologic Q4 2025 Quarterly FinancialsXBRL
Revenue
$1.0B
▲ +2.5% YoY
Net Income
$179M
▼ -10.9% YoY
Net Margin
17.1%
▼ -258bp YoY
Source: XBRL data from Hologic Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Hologic Quarterly Reports
Get deeper insights on Hologic
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.